SG11201704175WA - Hapten-enhanced chemoimmunotherapy by ultra-minimum incision personalized intratumoral chemoimmunotherapy - Google Patents

Hapten-enhanced chemoimmunotherapy by ultra-minimum incision personalized intratumoral chemoimmunotherapy

Info

Publication number
SG11201704175WA
SG11201704175WA SG11201704175WA SG11201704175WA SG11201704175WA SG 11201704175W A SG11201704175W A SG 11201704175WA SG 11201704175W A SG11201704175W A SG 11201704175WA SG 11201704175W A SG11201704175W A SG 11201704175WA SG 11201704175W A SG11201704175W A SG 11201704175WA
Authority
SG
Singapore
Prior art keywords
chemoimmunotherapy
intratumoral
hapten
personalized
ultra
Prior art date
Application number
SG11201704175WA
Inventor
Baofa Yu
Original Assignee
Baofa Yu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baofa Yu filed Critical Baofa Yu
Publication of SG11201704175WA publication Critical patent/SG11201704175WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/06—Phenols the aromatic ring being substituted by nitro groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/32—Tin compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
SG11201704175WA 2014-11-26 2015-11-24 Hapten-enhanced chemoimmunotherapy by ultra-minimum incision personalized intratumoral chemoimmunotherapy SG11201704175WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462085235P 2014-11-26 2014-11-26
PCT/US2015/062538 WO2016086070A1 (en) 2014-11-26 2015-11-24 Hapten-enhanced chemoimmunotherapy by ultra-minimum incision personalized intratumoral chemoimmunotherapy

Publications (1)

Publication Number Publication Date
SG11201704175WA true SG11201704175WA (en) 2017-06-29

Family

ID=56075014

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201704175WA SG11201704175WA (en) 2014-11-26 2015-11-24 Hapten-enhanced chemoimmunotherapy by ultra-minimum incision personalized intratumoral chemoimmunotherapy

Country Status (8)

Country Link
US (1) US11110303B2 (en)
EP (1) EP3223810A1 (en)
CN (1) CN107106531A (en)
AU (1) AU2015353539A1 (en)
CA (1) CA2968853A1 (en)
EA (1) EA201791126A1 (en)
SG (1) SG11201704175WA (en)
WO (1) WO2016086070A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108114280B (en) * 2017-12-26 2019-11-12 深圳大学 A kind of delivery system and preparation method thereof based on stannous sulfide nanometer sheet
CN113559269A (en) * 2021-08-26 2021-10-29 首都医科大学附属北京友谊医院 Application of inosine in preparation of anti-tumor medicine or anti-tumor medicine composition

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4160817A (en) 1976-09-29 1979-07-10 Research Corporation Application of protein-protein interaction as an assay for the detection of cancer
US4447526A (en) 1981-04-20 1984-05-08 Miles Laboratories, Inc. Homogeneous specific binding assay with carrier matrix incorporating specific binding partner
FR2505182A1 (en) 1981-05-07 1982-11-12 Battentier Eric Treatment of external-internal cancers, scirrhous and verrucous states - by injection of an ethanol, salicylic acid and hydrogen peroxide liquid, followed by a pomade of celandine plant, copper sulphate etc.
CA1262864A (en) 1982-09-17 1989-11-14 Clarence D. Cone Method for producing oncolysis
EP0240191A3 (en) 1986-03-13 1989-10-25 Seiko Instruments Inc. Method of isolating dna contained in a virus or cell
FR2604092B1 (en) * 1986-09-19 1990-04-13 Immunotech Sa IMMUNOREACTIVES FOR TARGETING ANIMAL CELLS FOR VISUALIZATION OR DESTRUCTION IN VIVO
US4804480A (en) 1986-12-29 1989-02-14 E. I. Du Pont De Nemours And Company Destruction of nitrophenols
JPH0629196B2 (en) 1987-12-01 1994-04-20 甲子郎 梅村 Physiological action enhancer for tumor treatment by ultrasound
US4832849A (en) 1988-06-16 1989-05-23 Merrell Dow Pharmaceuticals Inc. Extraction and purification of an anticoagulant principle from the south american leech, haementeria ghilianii
US5156841A (en) 1988-08-26 1992-10-20 United States Of America Anti-tumor vaccine
US5354690A (en) 1989-07-07 1994-10-11 Karl Tryggvason Immunological methods for the detection of the human type IV collagen α5 chain
US5005588A (en) 1989-10-13 1991-04-09 David Rubin Method for increasing tumor sensitivity to chemotherapy
US5215899A (en) 1989-11-09 1993-06-01 Miles Inc. Nucleic acid amplification employing ligatable hairpin probe and transcription
US5290551A (en) 1990-05-08 1994-03-01 Thomas Jefferson University Treatment of melanoma with a vaccine comprising irradiated autologous melanoma tumor cells conjugated to a hapten
MX9206309A (en) 1991-11-04 1994-05-31 David Rubin METHOD AND COMPOSITION TO TREAT TUMORS THAT HAVE HIGH ACTIVITY OF THYROSINASE.
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5993434A (en) 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5705151A (en) 1995-05-18 1998-01-06 National Jewish Center For Immunology & Respiratory Medicine Gene therapy for T cell regulation
JPH11514990A (en) 1995-09-25 1999-12-21 チャチョウア，サミー Use of 2-mercaptoethanolamine (2-MEA) and related aminothiol compounds and copper 3,5-diisopropylsalicylate (II) and related compounds for preventing and treating various diseases
WO1998003195A1 (en) 1996-07-18 1998-01-29 Arch Development Corporation Methods and compositions for modulation of growth response
KR20000076115A (en) 1997-03-10 2000-12-26 와일러 제임스 에프. Photodynamic therapy generated oxidative stress for temporal and selective expression of heterologous genes
JPH11171788A (en) 1997-12-11 1999-06-29 Toray Ind Inc Relapse suppressant for hepatocellular carcinoma c
CA2323074A1 (en) 1998-03-13 1999-09-16 Baylor College Of Medicine Compositions and methods for the treatment and prevention of metastatic disorders
SI1098641T1 (en) 1998-07-27 2016-08-31 St. Jude Pharmaceuticals, Inc. Chemically induced intracellular hyperthermia
US6248585B1 (en) 1998-11-19 2001-06-19 Thomas Jefferson University Compositions for preserving haptenized tumor cells for use in vaccines
US7067111B1 (en) 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
US6811788B2 (en) 2000-01-19 2004-11-02 Baofa Yu Combinations and methods for treating neoplasms
US7927612B2 (en) 2000-01-19 2011-04-19 Baofa Yu Combinations and methods for treating neoplasms
US7041302B2 (en) 2001-01-09 2006-05-09 Biother Corporation Therapeutic modulation of the tumor inflammatory response
GR1004600B (en) 2002-06-10 2004-06-18 Βιομεντικα Λαιφ Σαιενσις Ανωνυμη Εταιρια Φαρμακευτικων Προιοντων METHOD OF PREPARATION AND SYNTHESIS OF A KIT AND KIT FOR THE PREPARATION OF THE PEPTIDE C-AcaQALGNQAVGHLMNH2, ANALOGUE OF BOMBESIN (BN2), RADIO-LABELLED WITH THE RADIONUCLIDES Tc-99m AND rE-188. CLINICAL APPLICATION OF THE LABELLED ANALOGUES IN THE DIAGNOSIS AND THERAPY OF CANCER TUMOUR
CN101138634A (en) 2006-09-07 2008-03-12 于保法 Composition for treating tumour
CN101549153A (en) * 2008-04-02 2009-10-07 于保法 Composite and method for self-treating tumor

Also Published As

Publication number Publication date
US20190125778A1 (en) 2019-05-02
CA2968853A1 (en) 2016-06-02
WO2016086070A1 (en) 2016-06-02
US11110303B2 (en) 2021-09-07
CN107106531A (en) 2017-08-29
EP3223810A1 (en) 2017-10-04
AU2015353539A1 (en) 2017-07-13
EA201791126A1 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
GB201410971D0 (en) Vaccine
PT3092043T (en) Toy
SG10201502448TA (en) Self-assembling polymers - i
SG10201503758PA (en) Self-assembling polymers - vi
SG10201503803PA (en) Self-assembling polymers - iv
HK1243984A1 (en) Cardboard based unit
GB2535830B (en) Balloon
EP3231644A4 (en) Stabilizer
SG10201503006PA (en) Self-assembling polymers - ii
SI3097076T1 (en) Novel cyp-eicosanoid derivatives
GB201517285D0 (en) Stabilizer arrangement
HK1243341A1 (en) Reduced foaming vaccine compositions
PL3322718T3 (en) Histone anti-cancer vaccines
GB2547614B (en) Stabilizer
EP3045216A4 (en) Coupled balloon
EP3012005A4 (en) Balloon
SG10201503799TA (en) Self-assembling polymers - v
GB2532437B (en) Stabiliser
SG10201503013RA (en) Self-assembling polymers - iii
SG11201704175WA (en) Hapten-enhanced chemoimmunotherapy by ultra-minimum incision personalized intratumoral chemoimmunotherapy
GB201401749D0 (en) Folding tablechair
HK1221683A1 (en) Game controller
PL3228650T3 (en) Novel peg derivative
HUE053284T2 (en) Vaccine
GB201419891D0 (en) Game controller